Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vericel Corporation - Common Stock (NQ: VCEL )

39.73 -1.36 (-3.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
From Vericel Corporation
Via GlobeNewswire
Vericel's Short Report: Deep Dive Into Knee-Repair Focused Company's 27 Years of Losses
J Capital Research has released a short idea report on Vericel Corporation (NASDAQ: 
Via Benzinga
Vericel to Present at the Morgan Stanley Global Healthcare Conference
From Vericel Corporation
Via GlobeNewswire
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. 
Via Benzinga
Expert Ratings for Vericel
Via Benzinga
Vericel: Q1 Earnings Insights
Via Benzinga
Vericel Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Expectations for Vericel's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
From Vericel Corporation
Via GlobeNewswire
Analyst Ratings for Vericel
Via Benzinga
What's Going On With Vericel Shares Trading Higher
Vericel Corp (NASDAQ: VCEL) shares are trading higher by 13.63% to $27.10 Tuesday after the company reported preliminary FY22 revenue results. What Else? 
Via Benzinga
FDA Approves MediWound's NexoBrid For Burn Treatment
Via Benzinga
Vericel Corp. (NASDAQ: VCEL) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
From Vericel Corporation
Via GlobeNewswire
Looking Into Vericel's Return On Capital Employed
Via Benzinga
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
From Vericel Corporation
Via GlobeNewswire
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. 
Via Benzinga
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program
From Vericel Corporation
Via GlobeNewswire
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
From Vericel Corporation
Via GlobeNewswire
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
From MediWound Ltd.
Via GlobeNewswire
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
From Vericel Corporation
Via GlobeNewswire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.